跳至主要内容
临床试验/NCT04608448
NCT04608448已完成早期 1 期

An Innovative Proof-of-concept Approach to Identify Age-modulating Drugs Capable of Reversing Inflammation and Re-setting the Epigenetic Clock (Topical-RAPA)

The University of Texas Health Science Center at San Antonio1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2021年4月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
入组人数
22
试验地点
1
主要终点
Change in Epigenetic Markers

研究概览

简要总结

Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.

详细描述

Rapamycin 8% ointment will be applied topically to one of the participant's forearms and matching placebo to the opposite forearm daily for a total of 6 months. After consenting, screening and randomization of arms, the participants will be monitored at monthly visits until study completion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

Randomization will be performed by the compounding pharmacy. Ointment dispensers will be color-coded for left and right arm for each subject.

入排标准

年龄范围
65 Years 至 95 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • 65-95 years of age.
  • Good health with all chronic diseases (hypertension, coronary artery disease, etc.) clinically stable.
  • Selected subjects will be in good health (Per the World Health Organization, good health will be defined as complete physical, mental, and social well-being and not merely the absence of disease or infirmity).
  • All diseases or infirmities will be clinically stable whether managed by medications or not.
  • CLOX score of 10 or greater
  • Women will be postmenopausal
  • Postmenopausal women taking hormone replacement will be included if they have been on a stable dose for ≥6 months
  • Live within a 20 mile drive of the UTHSA campus (7703 Floyd Curl Drive, San Antonio, TX)

排除标准

  • Diabetes.
  • History of skin ulcers or poor wound healing, or keloid formers.
  • Liver disease.
  • Coumadin anti-coagulation.
  • Treatment with drugs known to affect cytochrome P450 3A (diltiazem, erythromycin, etc. - due to role in rapamycin metabolism).
  • Treatment with an immunosuppressant (prednisone, etc.) within 6 months.
  • History of recent (within 6 months) Myocardial Infarction or active Coronary Disease.
  • Hypersensitivity to rapamycin or petrolatum (ointment vehicle)
  • Arm tattoos or scars in application area

研究组 & 干预措施

Topical Rapamycin

Active Comparator

Ointment is applied to a color coded area on the subject forearm daily.

干预措施: Rapamycin Topical Ointment (Drug)

Placebo

Placebo Comparator

Placebo ointment is applied to a color coded area on the subject forearm daily.

干预措施: Placebo (Other)

结局指标

主要结局

Change in Epigenetic Markers

时间窗: Baseline to 6 months

A set of DNA methylation marks that correlate with chronological age will be used to measure rejuvenation of the "epigenetic clock" due to drug treatment compared to placebo. Using Illumina EPIC arrays, CpG methylation will be assessed and then the predicted age, based on the combined methylation at the set of 391 marks (the "epigenetic clock" as defined by Dr. Steven Horvath, UCLA), will be determined.

次要结局

  • Change in Inflammatory Marker IL-6(Baseline to 6 months)
  • Change in Inflammatory Marker CRP(Baseline to 6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ellen Kraig

Prof & Deputy Chair of Faculty Development Cell Systems & Anatomy

The University of Texas Health Science Center at San Antonio

研究点 (1)

Loading locations...

相似试验